Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

Autor: Luc R.C.W. van Lonkhuijzen, P.M.L.H. Vencken, Marc van Beurden, Caroline Seynaeve, Leendert H. Zaaijer, Joanne A. de Hullu, Ronald P. Zweemer, Marian J.E. Mourits, Brigitte F. M. Slangen, Hans F. A. Vasen, Muriel A. Adank, Mieke Kriege, Helena C. van Doorn, Katja N. Gaarenstroom

Publikováno v: British Jounal of Cancer, 115(10), 1174-1178. Nature Publishing Group
British Journal of Cancer, 115, 10, pp. 1174-1178
British Journal of Cancer, 115(10), 1174-1178. Nature Publishing Group
Zaaijer, L H, Van Doorn, H C, Mourits, M J E, van Beurden, M, de Hullu, J A, Adank, M A, van Lonkhuijzen, L R C W, Vasen, H F A, Slangen, B F M, Gaarenstroom, K N, Zweemer, R P, Vencken, P M L H, Seynaeve, C & Kriege, M 2016, ' Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers ', British Journal of Cancer, vol. 115, no. 10, pp. 1174-1178 . https://doi.org/10.1038/bjc.2016.333
British Journal of Cancer
British Journal of Cancer, 115, 1174-1178
British journal of cancer, 115(10), 1174-1178. Nature Publishing Group
British Journal of Cancer, 115(10), 1174-1178

Contains fulltext : 171109.pdf (Publisher’s version ) (Open Access) BACKGROUND: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c7bac045b2eaf71f4778c5fff40da6a
https://research.rug.nl/en/publications/10a9b997-872b-4519-8a67-bfba837eaf62